Envista (NYSE:NVST) Shares Cross Below Fifty Day Moving Average – Here’s Why

Envista Holdings Corporation (NYSE:NVST)’s stock price passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $24.59 and traded as low as $23.40. Envista shares last traded at $23.48, with a volume of 3,727,983 shares traded.

Analyst Ratings Changes

NVST has been the subject of several recent research reports. Weiss Ratings upgraded Envista from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 6th. Zacks Research cut Envista from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Morgan Stanley set a $23.00 target price on Envista in a research note on Thursday, August 6th. Robert W. Baird lowered Envista from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $34.00 to $26.00 in a report on Thursday, October 15th. Finally, Piper Sandler reduced their target price on Envista from $28.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 9th. Six research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat, Envista presently has a consensus rating of “Hold” and an average target price of $28.86.

Envista Trading Down 4.6%

The company has a debt-to-equity ratio of 0.47, a current ratio of 2.43 and a quick ratio of 2.07. The stock has a market cap of $3.77 billion, a P/E ratio of 40.48, a PEG ratio of 1.25 and a beta of 0.89. The firm’s fifty day moving average price is $24.59 and its two-hundred day moving average price is $25.71.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.07. Envista had a return on equity of 7.88% and a net margin of 3.33%. The company had revenue of $730.50 million during the quarter, compared to analyst estimates of $716.11 million. During the same quarter last year, the company earned $0.26 earnings per share. The firm’s quarterly revenue was up 7.1% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. As a group, equities research analysts forecast that Envista Holdings Corporation will post 1.53 EPS for the current year.

Insider Buying and Selling at Envista

In other Envista news, SVP Mischa Reis sold 8,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $27.50, for a total value of $220,000.00. Following the sale, the senior vice president owned 27,321 shares of the company’s stock, valued at $751,327.50. This trade represents a 22.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Envista in the second quarter valued at approximately $25,000. Provenance Wealth Advisors LLC bought a new stake in Envista during the third quarter valued at approximately $28,000. Nisa Investment Advisors LLC lifted its position in Envista by 116.4% during the third quarter. Nisa Investment Advisors LLC now owns 1,679 shares of the company’s stock valued at $39,000 after purchasing an additional 903 shares during the last quarter. Nykredit A S purchased a new position in Envista in the 2nd quarter worth approximately $52,000. Finally, C M Bidwell & Associates Ltd. purchased a new position in Envista in the 2nd quarter worth approximately $63,000.

Envista Company Profile

Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals.

Envista’s portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management.

Envista was established as an independent public company in 2019 following its separation from Danaher Corporation.